Q1 2026 · 13F-HR
NEA Management Company, LLCholdings as filed
Filed 2026-05-15 · accession 0001072613-26-000458
$1.76B
Reported value
26
Positions
2026-03-31
Period end
The Brief · NEA Management Company, LLC · Q1 2026
AI · grounded in 13F
NEA Management Company, LLC closed its position in Rhythm Pharmaceuticals, Inc. RYTM, reducing its exposure by $311.48M. The fund established a new position in Spyglass Pharma, Inc. SGP valued at $191.53M. Additionally, the fund trimmed its holdings in Celcuity Inc. CELC by 35.36% and Gossamer Bio, Inc. GOSS by 94.47%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03940C100 | ACLXGBX | Arcellx, Inc. | $349.7M | 19.9% | 3,045,262 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc. | $260.9M | 14.8% | 2,285,561 | Common | SOLE |
| 85220G109 | SGP | Spyglass Pharma, Inc. | $191.5M | 10.9% | 7,392,301 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics, Inc. | $157.7M | 8.97% | 13,222,228 | Common | SOLE |
| 805111101 | SVRA | Savara, Inc. | $133.6M | 7.60% | 24,471,264 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics, Inc. | $126.5M | 7.19% | 7,692,298 | Common | SOLE |
| 55287L101 | MBX | MBX Biosciences, Inc. | $107.9M | 6.13% | 3,614,486 | Common | SOLE |
| 98937L105 | ZBIO | Zenas BioPharma, Inc. | $78.7M | 4.47% | 4,023,219 | Common | SOLE |
| 22266M104 | COUR | Coursera, Inc. | $74.9M | 4.26% | 12,867,769 | Common | SOLE |
| 05156V102 | AUPH | Aurinia Pharmaceuticals, Inc. | $58.8M | 3.34% | 3,969,834 | Common | SOLE |
| 68622P109 | ORIC | ORIC Pharmaceuticals, Inc. | $52.2M | 2.97% | 4,118,621 | Common | SOLE |
| H17182108 | CRSP | CRISPR Therapeutics AG | $50.4M | 2.86% | 1,058,570 | Common | SOLE |
| 71722W107 | PHAT | Phathom Pharmaceuticals, Inc. | $21.8M | 1.24% | 1,960,169 | Common | SOLE |
| 126638105 | CVRX | CVRx, Inc. | $19.2M | 1.09% | 2,026,083 | Common | SOLE |
| 500946108 | KRRO | Korro Bio, Inc. | $14.7M | 0.84% | 1,297,893 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 Pharmaceuticals, Inc. | $13.4M | 0.76% | 3,233,743 | Common | SOLE |
| 15870P307 | CSBR | Champions Oncology, Inc. | $9.9M | 0.56% | 1,713,720 | Common | SOLE |
| 09203E105 | BDTX | Black Diamond Therapeutics, Inc. | $9.5M | 0.54% | 4,448,757 | Common | SOLE |
| 46124U107 | IVA | Inventiva SA | $8.0M | 0.46% | 1,462,586 | Common | SOLE |
| 65487U108 | NKTX | Nkarta, Inc. | $7.5M | 0.43% | 3,568,781 | Common | SOLE |
| 04746L203 | LONA | LeonaBio, Inc. | $4.8M | 0.27% | 464,398 | Common | SOLE |
| 81726A209 | — | Senti Biosciences, Inc. | $3.1M | 0.17% | 3,775,615 | Common | SOLE |
| 57055L206 | MRKR | Marker Therapeutics, Inc. | $2.1M | 0.12% | 1,625,678 | Common | SOLE |
| 68277Q105 | OKUR | OnKure Therapeutics, Inc. | $2.0M | 0.11% | 478,548 | Common | SOLE |
| 38341P102 | GOSS | Gossamer Bio, Inc. | $328,500 | 0.02% | 1,000,000 | Common | SOLE |
| 45175G207 | IMA | ImageneBio, Inc. | $250,025 | 0.01% | 50,005 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.